Progenics (PGNX) volatility elevated into FDA approval of constipation treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral Relistor
July 20, 2016 10:22 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the company and Valeant announced FDA approval of oral Relistor for the treatment of OIC in chronic non-cancer pain patients.
Aschoff commented, "Even with direct competitor Movantik on... More
Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & Company
July 20, 2016 9:16 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $11 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the FDA approved oral Relistor. He called it the first of many upcoming drivers for the stock.
Messer commented, "PGNX shares are indicated up... More
Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTOR
July 20, 2016 8:10 AM EDTProgenics Pharma (NASDAQ: PGNX) is ramping 21% in pre-open trade Wednesday after the company and Valeant Pharmaceuticals (NYSE: VRX) announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic... More
BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)
July 20, 2016 7:57 AM EDTBTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE: VRX)... More
